title: An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
abstract: BACKGROUND
  About one-third of breast and ovarian carcinoma patients have circulating antibodies reactive with polymorphic epithelial mucin (MUC1), either free or bound to immune complexes. While the presence of these immune complexes has prognostic significance in breast cancer patients, the significance of free MUC1 antibodies is less clear. The objective of this study was to develop a reliable assay for the accurate determination of circulating free antibodies to MUC1.
  
  
  METHODS
  We developed an enzyme-linked immunosorbent assay (ELISA) (PEM.CIg) employing a 60 mer peptide (a triple tandem repeat sequence of the MUC1 peptide core) conjugated to bovine serum albumin and peroxidase-labeled antihuman immunoglobulin G or M antibodies. The assay was standardized and its analytical performance evaluated. A total of 492 serum samples were obtained from 40 healthy men, from 201 healthy women (including 55 women without a history of pregnancy and 45 pregnant women), and (before primary treatment) from 62 benign breast tumor patients and 190 breast cancer patients. MUC1 serum levels were determined with commercial CA 15-3 tests.
  
  
  RESULTS
  Circulating antibodies to MUC1 are present both in healthy subjects and in breast cancer patients. The within- and between-assay coefficients of variation were, respectively, 2 and 12% for the IgG determinations and 1.2 and 3% for the IgM determinations. Correlation coefficients for serially diluted serum samples ranged from 0.9998 to 0.9920 for IgG and from 0.9996 to 0.9818 for IgM determinations. The reactivity of serum samples was partially blocked by the addition of various MUC1 peptides and by MUC1 mucin. The inhibiting effect of modified 60 mer peptides suggests the presence of antibodies directed to more than one epitope.
  
  
  CONCLUSIONS
  The PEM. CIg assay is a reliable ELISA for measuring free MUC1 antibodies in serum. We are in the process of relating the results obtained in the breast cancer group to disease outcome to evaluate its prognostic significance. In addition, the assay may become a useful tool for vaccine therapy monitoring.
authors.affiliation: Department of Obstetrics and Gynaecology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands. s.vonmensdorff@azvu.nl
authors.forename: S
authors.initials: S
authors.lastname: von Mensdorff-Pouilly
authors.forename: M M
authors.initials: MM
authors.lastname: Gourevitch
authors.forename: P
authors.initials: P
authors.lastname: Kenemans
authors.forename: A A
authors.initials: AA
authors.lastname: Verstraeten
authors.forename: G J
authors.initials: GJ
authors.lastname: van Kamp
authors.forename: A
authors.initials: A
authors.lastname: Kok
authors.forename: K
authors.initials: K
authors.lastname: van Uffelen
authors.forename: F G
authors.initials: FG
authors.lastname: Snijdewint
authors.forename: M A
authors.initials: MA
authors.lastname: Paul
authors.forename: S
authors.initials: S
authors.lastname: Meijer
authors.forename: J
authors.initials: J
authors.lastname: Hilgers
mesh_terms: D001323:Autoantibodies / Q000097:blood*; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D018396:Mucin-1 / Q000097:blood / Q000276:immunology*; D011247:Pregnancy
chemical_list: D001323:Autoantibodies; D018396:Mucin-1